On Tuesday, shares in Durham, North Carolina-based Quintiles IMS Holdings Inc. ended the session 0.11% lower at $71.66 with a total volume of 1.73 million shares traded. Quintiles IMS Holdings' shares have gained 8.49% in the past one year. Shares of the Company, which provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific, are trading at a PE ratio of 21.53. The stock is trading 2.83% above its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI) of 28.44.
On October 27th, 2016, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'. Visit us today and download your complete report on Q for free at:
PRA Health Sciences
Raleigh, North Carolina headquartered PRA Health Sciences Inc.'s stock finished Tuesday's session 0.45% lower at $52.98 with a total volume of 334,029 shares traded. Over the past three months and the previous one year, PRA Health Sciences' shares have gained 9.80% and 40.34%, respectively. Shares of the Company, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, are trading above its 200-day moving average by 12.86%. PRA Health Sciences' stock traded at a PE ratio of 45.83 and has an RSI of 43.91. The complimentary research report on PRAH can be accessed at:
On Tuesday, shares in Malvern, Pennsylvania headquartered BioTelemetry Inc. recorded a trading volume of 383,852 shares, which was higher than their three months average volume of 354,010 shares. The stock ended the day 1.98% higher at $18.05. Shares of the Company, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, are trading at a PE ratio of 39.07. BioTelemetry's stock has gained 28.65% in the past one year. The Company is trading above its 200-day moving average by 15.75%. Furthermore, shares of BioTelemetry have an RSI of 45.35. Register for free on Stock-Callers.com and download the PDF research report on BEAT at:
Gaithersburg, Maryland headquartered OpGen Inc.'s stock declined 4.76%, to close the day at $1.00. The stock recorded a trading volume of 197,795 shares. Shares of the Company, which engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, are trading 37.05% and 37.35% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 28.26. Get free access to your research report on OPGN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA